Introduction
Colorectal cancer (CRC) is the second most common cause of cancer-related mortality in the Western world 1 . Although it can spread in a variety of ways, lymphatic vessel (LV) invasion and metastasis are common in CRC early stages 2 . Previous studies have shown that vascular endothelial growth factor (VEGF) family members and their receptors (VEGFR) contribute to lymphangiogenesis and the metastatic process in CRC 2 . In fact, high levels of VEGFC and its receptor have been described to promote tumor-associated LV expansion, thus becoming one of the most efficient pathways in regulating lymphangiogenesis, during CRC dissemination [3] [4] [5] . However, functional studies regarding lymphangiogenesis and lymphatic metastasis are still lacking in CRC. The lymphatic system plays critical roles in the maintenance of fluid homeostasis, immune response, and cancer progression 6 , and to exert its biological functions it undergoes lymphangiogenesis, a process of growth and expansion of the lymphatic vessels. Lymphangiogenesis is activated by the binding of VEGFC and VEGFD to their receptor VEGFR3 7 , even if no association of VEGFD expression has been found with CRC lymphatic spread 8 . Even though VEGFC interacts with VEGFR2, which is primarily involved in the induction of angiogenesis 9 , one of the major physiological functions of this growth factor is generally accepted to be the inducer of LV growth 10 .
Tumor metastasis is responsible for most cancer related deaths. The metastatic process can be described in several steps which involve the transmigration of cancer cells from the primary tumor into the microvascular or the lymphatic endothelium (intravasation and/or extravasation), and subsequently, the formation of a secondary tumor at a distant targeted organ 11 . The experimental manipulation of VEGFC together with the blocking of VEGFR3 activation has been studied in several cancer animal models, providing functional evidences that VEGFC is able to induce tumor lymphangiogenesis, and concomitantly promote metastasis formation in various distant organs [12] [13] [14] . One of the main restrictions of tumor cell intravasation through the lymphatic system is LV integrity 15 , which is strictly related to the organization of interendothelial adherens junction proteins. These junctions are formed by the homotypic interaction of vascular endothelial cadherin (VE-Cad) 16 . Upon cell-cell adhesion, cadherin units form a core adhesion complex on adjacent cells via their extracellular domains 16 . In greater detail, the VE-Cad intracellular region forms a complex with an intracellular protein network, including α-, β-and γ-catenin and p120 17 , thus contributing to the strength of intracellular adhesion 18 . Phosphorylation of VE-Cad on Tyr residues disrupts endothelial cell adherens junctions by causing the dissociation of catenins from VE-Cad, facilitating the diapedesis of leukocytes and metastatic cancer cells 19 . It has been reported that an aberrant localization of VE-Cad on blood vessels is responsible for cancer cell M A N U S C R I P T
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6 intravasation and extravasation, thus increasing the metastatic spread of several tumors, including CRC 19 . VE-Cad expression on the microvascular endothelial cell membrane depends on its internalization and degradation, and one of the mechanisms mediating these two events is the activation of VEGFR2 by its ligand VEGFA 12 . No mechanistic data is however available regarding the role of VEGFR3 signaling on lymphatic endothelial cell adherens junctions during CRC spreading. In the present study, with the use of an orthotopic xenotransplantation mouse model of CRC, we demonstrate that VEGFC binding to VEGFR3 controls the metastatic spread through the maintenance of lymphatic endothelial barrier integrity.
Material and Methods (See also Supplemental Material and Methods) Patients
Tumoral colon tissues were obtained from surgical specimens of CRC patients at different TNM stages, ranging from pT1N0 to pT4N2bM1b. Healthy tissues from the intestine of patients admitted for bowel resection due to diverticulosis or polyps were used as controls. Specimens were formalin-fixed and paraffin-embedded or frozen in Cryoblock Compound (DiaPath) or frozen on dry ice and stored at −80°C. Human studies were approved by the ethics committee of the Istituto Clinico Humanitas.
Animals and animal handling
Mice used in this study were male BALB/c-Nude (CAnN.Cg-Foxn1nu/Crl) (Charles River Laboratories Italia, Lecco, Italy) 7-11 weeks old. All animals were maintained under pathogen-free conditions. Housing was temperature controlled, with a 12 light/12 dark hour cycle. Procedures involving mice conformed to institutional guidelines in agreement with national and international law and were approved by the ethics committee of the Humanitas Research Hospital.
Preparation of cell suspensions and transanal mucosal injection
CT26 mCherry positive cells were harvested from near-confluent cultures by a brief exposure to 0,5% trypsin and 0,02% EDTA (Lonza). Cells were washed with PBS 1X-/-and analyzed by FACS for mCherry positivity prior to injection. Mice were anesthetized with 100mg/kg ketamine and 50mg/kg xylazine. With the use of a 29-gauge syringe, 15000 CT26 mCherry-positive cells were injected submucosally into the distal posterior rectum in a final volume of 50µl, as previously described 20 .
Tumor growth was visually monitored daily. Mice were sacrificed on post-injection day 19. Test, as appropriate. Data were presented as means ±SD and differences were considered statistically significant when P ≤ 0,05.
Statistical analyses
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Results
Lymphatic vessel density and the VEGFC/VEGFR3 pathway are altered in human metastatic
CRC
Increased lymphatic vessel density in CRC is a key step for metastatic progression 5, 21 . For this reason we first evaluated lymphangiogenesis in colon tissues derived from CRC patients with negative (n=13) or positive (n=13) NM stage, and compared them to healthy controls (n=15). We performed an immunohistochemical staining for Podoplanin, a widely accepted marker of LVs 2 . Normal colonic biopsies showed sporadic thin LVs in the lamina propria and the submucosa, whereas CRC tissues both from non-metastatic (NM-) and metastatic (NM+) patients contained numerous LVs (Figure 1 A) .
Importantly, LVs within NM+ tumoral sections were loaded with metastatic cells (Figure 1 A, black arrows). Quantitative analysis revealed that LV density was significantly higher both in NM-and NM+ CRC patients, when compared to healthy tissue (Figure 1 B) , with no differences between NM-and NM+ subjects, thus revealing that lymphangiogenesis occurs in human CRC independently from the metastatic process.
To verify the involvement of VEGFC/VEGFR3 pathway in metastatic CRC-associated lymphangiogenesis, human healthy and malignant CRC biopsies were analyzed for the expression of these two molecules, by Real-Time PCR, Western blot and immunofluorescence. Figure 1 C showed that VEGFC-expression levels were up-regulated in mucosal extracts of CRC patients, when compared to control tissues, while the other VEGFR3 ligand, VEGFD didn't change. This is in accordance with other studies, showing reduced levels of VEGFD in metastatic CRC 8 ; for this reason the role of this specific growth factor was not taken into consideration for this study. Notably, VEGFR3-expression levels were up-regulated in mucosal extracts from CRC patients, when compared to healthy counterparts ( Figure 1 D) . Moreover, frozen-sections were double-stained for LYVE-1 and VEGFR3
( Figure 1 E) and their mean of fluorescence intensity (MFI) quantified, as recently described 22 . A lymphatic specific increase of VEGFR3 (Figure 1 F, left panel) but not LYVE-1 ( Figure 1F , right panel) in CRC sections was observed compared to control tissues, indicating that the tumor microenvironment increases VEGFR3 expression on individual LVs. Collectively, these data M A N U S C R I P T
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demonstrate that lymphatic vascularization is increased in human metastatic CRC, and suggest that the tumor microenvironment stimulates the VEGFC/VEGFR3 pathway on LVs, rather than VEGFD/VEGFR3 pathway, a finding compatible with tumor-induced lymphangiogenesis.
The VEGFC/VEGFR3 pathway is actively involved in the metastatic process of a CRC orthotopic model
In several cancer animal models, VEGFC has been found to enhance the passage of metastasis through We then evaluated whether the hastened VEGFC/VEGFR3-dependent metastatic dissemination correlated with altered lymphangiogenesis. For this purpose colons from CRC-bearing mice treated with VEGFC or mF431C1 were evaluated for LV expansion both in terms of LV density and size. 
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Taken together, these results suggest that VEGFC-dependent VEGFR3 activation impairs cell-cell adhesion by inducing the disassembly of the VE-Cad-β-catenin complex at intercellular junctions.
VEGFR3 activation by VEGFC alters HILEC permeability and affects CT26 cell transdentothelial migration
Cell-cell adherens junctions are important for endothelial barrier function and integrity 16 . 
LVs in tumor tissue of metastatic CRC patients displayed decreased VE-Cad levels
To confirm what was observed in vivo and in vitro, we further evaluated VE-Cad expression levels on LYVE-1+ vessels in metastatic CRC patients, and compared them with controls. Normal colon tissues showed a strong expression of VE-Cad on LVs, whereas CRC sections had a significant cadherin decrease ( 
Discussion
Tumor induced-angiogenesis and lymphangiogenesis are thought to expedite cancer cell entry into the blood and lymphatic vasculature, thus fostering metastatic dissemination 14 . However, while the role of the vascular endothelium in cancer progression is well described 26 , the contribution of tumoral LVs is still unclear. In many types of human cancers, including CRC 3-5 , the expression of VEGFC 2 and its receptor, VEGFR3 25, 27 , correlates with lymphangiogenic sprouting, metastases and poor prognosis. In accordance with these studies, we confirmed that active lymphangiogenesis takes place in CRC patients displaying a high expression of VEGFC and increased VEGFR3 levels on LVs. VEGFD is also known to be a VEGFR3 ligand and is considered an important pro-lymphangiogenic factor 28 ; however, unlike VEGFC, it was not altered in CRC patients, and for this reason our study only focused on VEGFC.
Several cancer animal models have highlighted the importance of the lymphatic vasculature in metastatic dissemination thanks to the modulation of the VEGFC/VEGFR3 pathway. In fact, He et al.
demonstrated in a mouse model of lung cancer, that VEGFC-overexpressing LNM35 cells induce massive lymphangiogenesis together with lymphatic activation, thus facilitating tumor cell entry in LVs and promoting metastatic dissemination to LNs 14 . Notably, in this study LV destabilization and tumor metastases were blocked using an Adenovirus producing a soluble VEGFR3-Ig fusion protein 14 .
Moreover, Matsumoto et al. showed that in a mouse model of breast cancer, VEGFR3 signaling was required for the early events of the metastatic process and that mF431C1 was able to block both tumor lymphangiogenesis and metastases 27 . In a similar way, our study shows that LVs undergo dramatic lymphangiogenic changes in response to nearby CT26 mCherry cells, including sprouting and dilation of the larger collecting vessels draining the tumor area. We demonstrate for the first time that upon VEGFR3 inhibition, tumor-lymphangiogenesis represents a rate-limiting step for CRC lymphogenous metastases, which are significantly suppressed at distant organs. In contrast, upon systemic VEGFC delivery, metastasis is fostered in association with active lymphangiogenesis. Consistent with other findings, in the tumoral context we do not observe any effects on blood vessel density and enlargement upon VEGFC treatment 29, 30 or VEGFR3 inhibition 7 . It is worthy of note that these experiments do not M A N U S C R I P T
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exclude the possibility that VEGFC could act on other cells other than lymphatic endothelial cells, such as VEGFR3-expressing macrophages 25 .
It is still unclear whether tumor cell intravasation/extravasation requires the transmigration of cancer cells through the cytoplasm of endothelial cells, as occurs for leukocytes, or whether they transmigrate between two adjacent endothelial cells after the disruption of cell-cell connections 19 . The endothelial barrier integrity is maintained by a complex balance between cell-to-cell adherens junctions. In some pathological conditions, such as inflammation and cancer, endothelial junctions can be disrupted leading to the opening of intercellular gaps and inducing increased vascular permeability 31 . We focused our attention on the most important player in maintaining barrier integrity: VE-Cad. In fact, blocking VE-Cad is sufficient to destabilize endothelial cell contacts in vivo and to increase vascular permeability 32 . In contrast, stabilizing endothelial cell junctions by enhancing the VE-Cad adhesive function in knock-in mice leads to the induction of vascular permeability and leukocyte extravasation 3, 33 . One of the mechanisms involved in adherens junction destabilization is the activation of VEGFR2
by VEGFA which induces VE-Cad tyrosine phosphorylation and its internalization 16 . In this scenario, VEGFA facilitates cancer cell intravasation by disrupting the VE-Cad-β-catenin complex and inducing adherens junction weakness and formation of transcellular holes 34 . Weis et al., provided evidence that VEGFA-mediated breakdown in blood endothelial integrity through VE-Cad disruption hastens metastases 19 . Moreover, they demonstrated that VE-Cad inhibition compromises endothelial barrier function and promotes tumor cell extravasation 19 . We hypothesized that similarly to blood vessels, the lymphatic vasculature could respond to the modulation of the VEGFC/VEGFR3 pathway with VE-Cad redistribution. In vitro results on HILEC confirmed our hypothesis; in fact, VEGFC-induced VEGFR3 signaling led to VE-Cad-β-catenin complex dissociation, VE-Cad internalization and β-catenin cytoplasmic release. Breslin et al. demonstrated that VEGFC-dependent VEGFR3 activation significantly increased lymphatic endothelial cell permeability 35 . In accordance with the above study, we provide in vivo evidence that VEGFR3 signaling induces major alterations in the intestinal lymphatic barrier and strongly impairs its functionality. Importantly, we propose a mechanism of CRC cell intravasation/extravasation that is dependent on VEGFR3 activation on lymphatic endothelial cells which facilitates tumor cell entry/exit in a VEGFC-dependent manner. The most intriguing and novel finding of our study is that the increased metastasis formation in VEGFC-treated mice during CRC progression is not only a consequence of enhanced lymphangiogenesis, but could also be a result of VE-Cad distribution and localization on LVs. In fact, VEGFC stimulates LVs sprouting and dilation, but also modulates VE-Cad expression on intestinal lymphatics. These results are in accordance with M A N U S C R I P T 15 , showing an overall survival benefit in patients with refractory metastatic CRC 40 .
In summary, our findings strongly support and encourage a VEGFC/VEGFR3-targeted therapy for the prevention of CRC metastatic dissemination. The inhibition of this signaling pathway may reduce tumor lymphangiogenesis and restore lymphatic barrier integrity through the maintenance of VE-Cad distribution on LVs. The lymphatic vasculature may thus represent a potent target to abate and prevent CRC lymphogenous spread. 
Immunohistochemical staining of Human Colonic Tissues
To quantify lymphatic vessel (LV) density, the number of Podoplanin-positive LVs was assessed in tumor areas of surgical specimens from patients with CRC. Normal areas of the intestine from patients admitted for bowel resection due to diverticulitis or polyps were used as controls (NL, n=15). Tissues were fixed in 4% buffered formalin, processed, and stained with haematoxylin (DAKO) and eosin 
Real-Time PCR
RNA was extracted from human tumor and healthy specimen or from healthy mouse colon and CT26
cell line using the PureZOL RNA isolation reagent (BIORAD) according to manufactured instructions.
RNA retrotranscription was performed with High Capacity cDNA Reverse Transcription Kits (Applied Biosystems®). Real-Time PCR analyzes were performed starting with cDNA obtained from human NM+ tumor (n=13) or healthy (n=13) tissues or from CT26 cell line and mouse colon used as control.
The primer pairs used are summarized in the table below:
The reactions were performed on ViiA™7 Real-Time PCR System (Applied Biosystems). GAPDH expression was used as housekeeping gene. Data were calculated using the 2^-∆Ct method. 
Cell line culture condition and infection
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VEGFR3 antibody blockade
Mice were given intra-peritoneal injections of an anti-mVEGFR3 antibody, mF431C1, (clone 31C1, ImClone Systems, 800 µg/100 µl of PBS per mouse) 4, 5 . Mice were administered intra-peritoneal injections three times per week for the entire experiment, starting from the first day after CT26 mCherry cell injections. A group of mice were sacrificed at 0, 5, 12, and 19 days after CT26 injection and mucosal extracts were analyzed by western blot for assessment of VEGFR3 inhibition. All experiments were performed in triplicate, using 4-8 mice per experimental group.
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Adenoviral human VEGFC administration
Mice were given intra-venous injections of an engineered adenovirus encoding human VEGFC (AdVEGFC), or control virus encoding GFP (AdGFP) (not shown) (5x10 8 PFU/mouse; ViraQuest) 5 7 days before CT26 mCherry cell injections. A group of mice were sacrificed at -7, 5, 12, and 19 days from CT26 injection, and mucosal extracts were analyzed by western blot for assessment of human VEGFC production. Adenoviral preparation was free from contamination with helper viruses, bacteria or lipopolysaccharide. All experiments were performed in triplicate, using 4-8 mice per experimental group.
Tumor dimension
Before being sacrificed mice were anesthetized with 100mg/kg ketamine and 50mg/kg xylazine and fluorescent imaging were performed using a Caliper Xenogen IVIS® Spectrum (Caliper Life Sciences, 
CT26 proliferation and invasion assay
A crystal violet assay was used to assess CT26 proliferation, as described previously 6 . Briefly, CT26
cells were seeded in 96-well cell culture plates (1×10 3 cells/well) with complete growth medium containing 1% fetal calf serum, and either left untreated or treated with human recombinant VEGFC (100 ng/ml; R&D system) or mF431C1 (300 µg/ml, Imclone). Medium was changed every other day and after 3 days in culture, cells were stained with 0.2% crystal violet (Sigma) dissolved in ethanol.
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Uptake of dye by cells on plates was eluted with 33% acetic acid in water. Plates were gently shaken for 20 minutes and the absorbance at 560 nm was measured by a Versamax microplate reader (Molecular Devices) at a wavelength of 560 nm. The optical density of each sample was then compared with a standard curve, in which the optical density was directly proportional to known cell numbers.
Invasion assay was assessed by using a BD BioCoat Matrigel invasion chamber with polycarbonate filters (8-µm pore size; BD Biosciences), 24 hours serum starved CT26 80x10 3 /filter were plated in the upper chamber in DMEM medium, both the upper and the lower chamber were supplemented with human VEGFC (100 ng/ml; R&D system) and/or SAR131675 (23 nM dissolved in DMSO; Selleckchem). After 16 hours, medium was removed from both chambers, and cells that had migrated onto the lower surface of the porous membrane were washed twice in PBS and stained with Diff Quick (Medion Diagnostics), according to the manufacturer's instruction. Triplicates of migrated cells were counted in 5 consecutive fields using a 10x objective. All experiments were performed in triplicate.
Metastasis dissemination assessment
At the indicated time point mice were sacrificed and liver, lungs, and draining lymphnodes were taken for metastasis evaluation by FACS analysis, as previously described 7 , and a piece of mCherry tumor was used as a positive control. Briefly organs were disrupted through a 70 µm filter (BD Falcon) with a 1 ml syringe plunger and washed with 10 ml of RPMI medium supplemented with 10% fetal calf serum and 20 mM Hepes. Liver and lungs were then centrifuged at 800 rpm for 10 minutes to discard debris.
ACK lysis buffer was used directly on pellets to remove red blood cells. All samples were washed with RPMI medium and centrifuged. Samples were then suspended in PBS and counted. 5x10 6 
Morphometric and immunofluorescence intensity measurements
Morphometric analysis of colon whole mounts was performed by 3D visualization of LVs. Images were taken as a z series stack using a 10x objective, and analyzed by Imaris Bitplane software, thus allowing visualization of the LVs in the submucosal and serosal-muscular layers. Tubule formation assay, migration assay and proliferation assay HIBEC tube formation was assessed using Matrigel (BD Biosciences) as previously describe 5 . Briefly, multiwell dishes were coated with 250 µL of complete medium containing 5 mg/ml Matrigel for 30 minutes at 37°C HIBEC were seeded in triplicate at a density of 5×10 4 in complete MCDB131 medium infected with AdVEGFC, AdGFP or untreated. Cells were cultured on Matrigel for 4 hours, and inverted phase-contrast microscopy was used to assess and count endothelial tube-like structures. Five high-power fields per condition were examined. All experiments were repeated three times.
Migration assay was assessed as previously reported 9 , with some modifications. By using a BD BioCoat Matrigel invasion chamber with polycarbonate filters (8µm pore size; BD Biosciences), starved (MCDB131 for 18 hours) HIBEC (50 x 10 3 /filter) were plated in the upper chamber in MCDB131 medium. After 18 hours, medium was removed from both chambers, and cells that had 
